Phase I LITESPARK-001 Study of Belzutifan for Advanced Solid Tumors: Extended 41-Month Follow-Up in the Clear Cell Renal Cell Carcinoma Cohort.
EUROPEAN JOURNAL OF CANCER（2024）
Key words
Belzutifan,Renal cell carcinoma,Hypoxia-inducible factor 2,Kidney cancer
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined